spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  anti-TNF 

 HSMN NewsFeed - 6 Aug 2021
BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA(R) (pembrolizumab) in Patients with Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2020
CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Nov 2020
Innovent Announces NMPA Granted New Indication Approval for SULINNO(R) (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Sep 2020
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Nov 2019
Araim Pharmaceuticals Selects Ferry Breedveld as Acting CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Oct 2019
AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ(TM)) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Jun 2019
Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Feb 2019
AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jan 2019
Oculis Expands Portfolio with the In-Licensing of a Novel Phase II-stage Anti-TNF Alpha Antibody Fragment
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 4 Jan 2019
Oculis Raises CHF15.5 Million in an Extension of its Series B Financing Round - Total Raised CHF35.5 Million
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 23 Jul 2018
Sangamo Therapeutics to Acquire TxCell
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 12 Dec 2017
Eyevensys Appoints Dr. Patricia Zilliox as Chief Executive Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 29 Nov 2017
Aethlon Medical Names Dr. Charles J. Fisher Chairman of the Board
Devices Personnel
 HSMN NewsFeed - 4 Sep 2017
Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 30 Mar 2017
U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA(R) (adalimumab) Prescribing Information
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Mar 2017
Eyevensys Appoints Leading Life Sciences Executive and Ophthalmology Expert Dr. Garth Cumberlidge as Chairman
Biopharmaceuticals Devices Ophthalmology Personnel
 HSMN NewsFeed - 15 Sep 2016
Eyevensys Announces Series A Extension Bringing Total Capital Raised to €9 Million
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 8 Aug 2016
Araim Pharmaceuticals Announces Appointment of Ferdinand C. Breedveld, M.D. as Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2016
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Mar 2016
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 Jan 2016
BENEPALI(R), the First Etanercept Biosimilar Referencing Enbrel(R), Approved in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jan 2016
Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Dec 2015
Amgen's First Biosimilar Marketing Authorization Application Submitted To European Medicines Agency For ABP 501
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Sep 2015
AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 9 Dec 2014
Zydus Launches World's First Biosimilar of Adalimumab
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 15 Oct 2014
Selecta Announces More than $20 Million in Equity Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Dec 2013
Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe
Biopharmaceuticals
 HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Apr 2013
Covagen Names Elias Papatheodorou Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Dec 2012
Avaxia Biologics Raises $6.4 Million in Series B Financing
Biopharmaceuticals Gastroenterology Venture Capital
 HSMN NewsFeed - 12 Nov 2012
Abbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2012
U.S. Food and Drug Administration Approves Pfizer’s XELJANZ(R) (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Oct 2012
Abbott Announces Three-Year Long-Term Data Evaluating Efficacy with HUMIRA(R) (Adalimumab) For Patients with Moderately to Severely Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Jun 2012
AstraZeneca And Rigel Sign Worldwide License Agreement For A Potential New Treatment For Chronic Asthma
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Peripheral Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2012
Abbott Announces 10-Year Data Evaluating HUMIRA(R) (Adalimumab) for Patients with Long-Standing Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-radiographic Axial Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 20 Jan 2012
Remicade(R) (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 7 Nov 2011
Abbott Presents HUMIRA(R) (Adalimumab) Phase 3 Study Results for Patients with Active Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2011
Abbott to Present Broad Spectrum of Compelling Data for HUMIRA(R) (Adalimumab) at American College of Rheumatology Annual Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2010
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE(R) After Inadequate Response to Enbrel(R) or Humira(R) Demonstrate Marked Clinical Improvement
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2010
New Magnetic Resonance Imaging (MRI) Data Show Efficacy of SIMPONI(R) in Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 27 Sep 2010
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI(R) Label in Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Jul 2010
European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Apr 2010
REMICADE(R) Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 9 Jan 2010
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Oct 2009
New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 26 Oct 2009
Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 6 Oct 2009
SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Jun 2009
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 13 May 2009
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Apr 2009
SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Feb 2009
Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Jan 2009
Cephalon Signs Option Agreement to Acquire Ception Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2008
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2008
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2008
New Study Shows ENBREL(R) (etanercept) Is More Effective than a DMARD in the Treatment of Symptoms of Ankylosing Spondylitis Patients
Biopharmaceuticals
 HSMN NewsFeed - 6 Oct 2008
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Sep 2008
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 27 Jun 2008
Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals
 HSMN NewsFeed - 24 Jun 2008
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 13 Jun 2008
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Biopharmaceuticals
 HSMN NewsFeed - 12 Jun 2008
New Data Demonstrates Joint Damage is Inhibited With Wyeth's Biologic Enbrel(R) Plus Methotrexate in Patients With Early Active Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2008
Phase 3 Data Show Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-TNF Agents
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2008
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jun 2008
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2008
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Apr 2008
FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 22 Apr 2008
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 18 Mar 2008
Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Mar 2008
UCB: Early Data on Cimzia(R) from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn's Disease Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 6 Feb 2008
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Jan 2008
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2008
Medivation Names Rohan Palekar Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2007
Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
Biopharmaceuticals Distribution
 HSMN NewsFeed - 21 Nov 2007
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2007
UCB to Appeal European Negative Opinion on CIMZIA(R) for the Treatment of Patients with Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 8 Nov 2007
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms Of Ankylosing Spondylitis According to Phase 3 Study Findings
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2007
Can-Fite: CF101 May Be Effective for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 20 Jul 2007
Biotechnology Start-up Nuon Therapeutics Inc. Completes $5 Million Series A Financing and Names Management Team
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 18 Jul 2007
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 10 Jul 2007
ACTEMRA(TM) (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2007
CIMZIA(TM) Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2007
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 7 Jun 2007
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 31 May 2007
Ception Therapeutics Raises Additional $14.7 Million Bringing Total Series C Financing to $77 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 May 2007
UCB Presents Long-Term CIMZIA(TM) Data in Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 4 May 2007
Royalty Pharma Acquires a Portion of New York University's Royalty Interest in Remicade(R) for $650 Million
Biopharmaceuticals
 HSMN NewsFeed - 4 May 2007
Abbott's Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 27 Apr 2007
Abbott's HUMIRA(R) (Adalimumab) Receives Positive Opinion from European Medicines Agency for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 26 Mar 2007
European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
Biopharmaceuticals Regulatory Gastroenterology
 HSMN NewsFeed - 23 Mar 2007
UCB Provides Update on CIMZIA(TM) for Crohn's Disease and Rheumatoid Arthritis in the US
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 27 Feb 2007
HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 23 Feb 2007
Significant Phase III Results with CIMZIA(TM) in Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2007
MedImmune Further Expands its Commercial Organization Expertise With Appointment of Two Additional Vice Presidents
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 30 Jan 2007
Ception Therapeutics Raises $63 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Jan 2007
Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
Regenerative Medicine Gastroenterology
 HSMN NewsFeed - 22 Dec 2006
UCB Announces Positive Results From Two New Phase III Studies in Rheumatoid Arthritis and Provides Update on the Status of US Approval for CIMZIATM in the Treatment of Crohn's Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Nov 2006
ORENCIA(R) (abatacept) or REMICADE(R)(infliximab) Demonstrated Superior Efficacy to Placebo at Six Months With ORENCIA Demonstrating Both Durable Efficacy and a More Favorable Safety Profile Through 12 Months
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
Two-Year Data for ORENCIA(R) (abatacept) Demonstrate Continued Efficacy in Adults With Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2006
Royalty Pharma Announces Agreement Regarding the Purchase of the Rights to a Pre-Existing Royalty Interest in HUMIRA(R) From AstraZeneca and CAT
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2006
TYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Data Show CIMZIA(TM) (certolizumab pegol) May Improve Productivity in Work and with Daily Activities for People with Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Analysis Shows CIMZIA(TM) (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Efficacy Data Show CIMZIA(TM) (Certolizumab Pegol) Maintained Response and Remission in Crohn's Patients Previously Treated With Infliximab
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Oct 2006
FDA Expands REMICADE(R) Indication for Ulcerative Colitis: Biologic Maintains Long-Term Clinical Remission and Mucosal Healing
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 17 Oct 2006
Paul Strauss, M.D. Joins Omeros as VP, Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Sep 2006
FDA Approves REMICADE(R) for Treatment of Chronic Severe Plaque Psoriasis: Marks Major Milestone for Patients With High Disease Burden
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Sep 2006
Abbott Submits U.S. and E.U. Regulatory Applications Seeking Approval for HUMIRA(R) (Adalimumab) as a Treatment for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 22 Jun 2006
Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the European Rheumatology Meeting
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
New Analysis Showed Ulcerative Colitis Patients in Clinical Remission Had Higher Rates of Employment and Lower Rates of Disability
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2006
New CIMZIA (TM) Data from PRECiSE Program Reinforce Robust Efficacy in Once-Monthly Treatment of Crohn's Disease and Consistent Tolerability Profile
Biopharmaceuticals Gastroenterology
Return to NewsFeed  

 Additional items found! 101

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 101 additional stories matching:
anti-TNF
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!